US And Europe Drug Reforms Will Erode Pricing Power

AN
AnalystLowTarget
AnalystLowTarget
Not Invested
Consensus Narrative from 19 Analysts
Published
28 Jul 25
Updated
28 Jul 25
AnalystLowTarget's Fair Value
UK£109.16
1.3% overvalued intrinsic discount
28 Jul
UK£110.54
Loading
1Y
-12.9%
7D
-3.9%

Author's Valuation

UK£109.2

1.3% overvalued intrinsic discount

AnalystLowTarget Fair Value